CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ZMD has developed ONCARIN, an immunotherapy for colorectal cancer that uses live bacteria to enhance immune response and destroy cancer cells. This treatment is cost-effective and aims to improve patient outcomes while reducing healthcare costs.
Following 30 years of research, ZMD has developed ONCARIN; an immunotherapy treatment for the treatment and to boostto immune system of patients with colorectal cancer.
The treatment consists of special developed capsules containing alyophilized mixture of live bacteria (colon flora) with a high oncolytic activity. ONCARIN has the unique ability to both inducecancer cell destruction and activate the immune system.
Furthermore the technology allows for an easy synthesis andmanufacture enabling th…
Z.M.D MEDICAL LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
